Patients who monitor only weight and ignore blood sugar, blood pressure, lipid levels, and inflammatory markers miss important signals about when to continue, taper, or adjust treatment
The glucagon agonism increases energy expenditure (burning more calories), while GLP-1 and GIP agonism suppress appetite
The clinician must review the specific medications, dosing, treatment response, side effects, and relevant health conditions
On the other hand, the mechanisms and changes on the longer-term GLP-1 drug scale are poorly understood
Creating balanced, healthy meals from low-calorie, nutrient-dense foods Disclaimer: The primary purpose of this blog post is to inform and entertain